25th octubre 2023
Últimas noticias
Encuentre cualquiera de nuestros más recientes comunicados de prensa, manténgase actualizado con las últimas noticias e infórmese sobre los próximos eventos a los que acudirá Curium.
7th septiembre 2023
Curium announces exclusive distribution agreement in Switzerland with b.e. Imaging for PYLCLARI™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
15th agosto 2023
Curium announces achievement of co-primary endpoints in phase 2 of its phase 1/2 SOLAR clinical trial imaging men with histologically-proven prostate cancer using copper Cu 64 PSMA I&T
28th julio 2023
Curium receives marketing authorization in the EU for Pylclari™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
25th julio 2023
Curium announces license and development agreement with Lantheus for AI-based PSMA PET software in Europe
21st julio 2023
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
21st julio 2023
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
23rd mayo 2023
Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T
2nd mayo 2023
Curasight and Curium announce global partnership for uTRACE® in prostate cancer
14th marzo 2023
Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial
2nd marzo 2023
Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO
21st diciembre 2022
Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99
24th noviembre 2022